Literature DB >> 20085491

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Roy T Steigbigel1, David A Cooper, Hedy Teppler, Joseph J Eron, Jose M Gatell, Princy N Kumar, Jurgen K Rockstroh, Mauro Schechter, Christine Katlama, Martin Markowitz, Patrick Yeni, Mona R Loutfy, Adriano Lazzarin, Jeffrey L Lennox, Bonaventura Clotet, Jing Zhao, Hong Wan, Rand R Rhodes, Kim M Strohmaier, Richard J Barnard, Robin D Isaacs, Bach-Yen T Nguyen.   

Abstract

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20085491      PMCID： PMC6076431          DOI： 10.1086/650002

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

1.  Statistics in medicine--reporting of subgroup analyses in clinical trials.

Authors:  Rui Wang; Stephen W Lagakos; James H Ware; David J Hunter; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

2.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

3.  Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

Authors:  Jose M Gatell; Christine Katlama; Beatriz Grinsztejn; Joseph J Eron; Adriano Lazzarin; Daniel Vittecoq; Charles J Gonzalez; Robert M Danovich; Hong Wan; Jing Zhao; Anne R Meibohm; Kim M Strohmaier; Charlotte M Harvey; Robin D Isaacs; Bach-Yen T Nguyen
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

4.  Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Havilland Campbell; Kim M Strohmaier; Hong Wan; Robert M Danovich; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

5.  Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors:  Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

6.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  6 in total
  76 in total

1.  Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.

Authors:  Matthew L Rizk; Yaming Hang; Wen-Lin Luo; Jing Su; Jing Zhao; Havilland Campbell; Bach-Yen T Nguyen; Peter Sklar; Joseph J Eron; Larissa Wenning
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

3.  Characterization of binding of raltegravir to plasma proteins.

Authors:  Caroline Barau; Valérie Furlan; Yazdan Yazdanpanah; Catherine Fagard; Jean-Michel Molina; Anne-Marie Taburet; Aurélie Barrail-Tran
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

4.  Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Authors:  Ahmed M Bayoumi; Paul G Barnett; Vilija R Joyce; Susan C Griffin; Huiying Sun; Nick J Bansback; Mark Holodniy; Gillian Sanders; Sheldon T Brown; Tassos C Kyriakides; Brian Angus; D William Cameron; Aslam H Anis; Mark Sculpher; Douglas K Owens
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

5.  Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.

Authors:  Christopher B Hurt; Sonia Napravnik; Richard D Moore; Joseph J Eron
Journal:  Antivir Ther       Date:  2014-01-23

6.  Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.

Authors:  Ashley N Brown; Jonathan R Adams; Dodge L Baluya; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

7.  A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

Authors:  Ighovwerha Ofotokun; Anandi N Sheth; Sara E Sanford; Kirk A Easley; Neeta Shenvi; Kelly White; Molly E Eaton; Carlos Del Rio; Jeffrey L Lennox
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

8.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

9.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

10.  Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.

Authors:  James H Willig; Sara-Anne Wilkins; Ashutosh Tamhane; Christa R Nevin; Michael J Mugavero; James L Raper; Laura A Napolitano; Michael S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-05       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.